Evidence map›Paper›PMID 42614263›Full record

ArticleFrontiers in immunology2026

Influence of immune checkpoint inhibitor target and timing on combination treatment with antibody-based β-emitting targeted radionuclide therapy across tumor immunogenicity profiles.

Simone C Kleinendorst, Egbert Oosterwijk, Mark Konijnenberg, Milou Boswinkel, Manon Gloudemans, Sylvia T M Wenker, Stijn Muselaers, Peter Mulders, Lyndsey Maffa, Michael F O'Hara and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Simone C KleinendorstDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Egbert OosterwijkDepartment of Urology, Radboud University Medical Center, Nijmegen, Netherlands.
Mark KonijnenbergDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Milou BoswinkelDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Manon GloudemansDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Sylvia T M WenkerDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Stijn MuselaersDepartment of Urology, Radboud University Medical Center, Nijmegen, Netherlands.
Peter MuldersDepartment of Urology, Radboud University Medical Center, Nijmegen, Netherlands.
Lyndsey MaffaTelix Pharmaceuticals Limited, Melbourne, VIC, Australia.
Michael F O'HaraTelix Pharmaceuticals Limited, Melbourne, VIC, Australia.
Michael P WheatcroftTelix Pharmaceuticals Limited, Melbourne, VIC, Australia.
Kwame Twumasi-BoatengTelix Pharmaceuticals Limited, Melbourne, VIC, Australia.
Sandra HeskampDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Targeted radionuclide therapy (TRT) and immune checkpoint inhibition (ICI) could be a highly effective combination treatment due to potential synergistic effects. In this study, we investigated two clinically relevant antibody-based radiopharmaceuticals labeled with lutetium-177: [ Methods: C57BL6 hPSMA transgenic mice bearing subcutaneous MC38-hPSMA or B16F10-hPSMA tumors were injected with [ Results: In the MC38-hPSMA model, a subtherapeutic [ Discussion: These findings indicate that

Indexed as

Immune Checkpoint InhibitorsRadioisotopesRadiopharmaceuticalsAnimalsAntigens, SurfaceCarbonic Anhydrase IXCell Line, TumorGlutamate Carboxypeptidase IIHumansLutetiumMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicAntigens, SurfaceCarbonic Anhydrase IXGlutamate Carboxypeptidase IIImmune Checkpoint InhibitorsLutetiumLutetium-177RadioisotopesRadiopharmaceuticalscombination treatmentimmune checkpoint inhibitionsyngeneic animal modeltargeted radionuclide therapytumor immunogenicity

Identifiers

PMID42614263
PMCPMC13481358

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.